Skip to main
WVE
WVE logo

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences Ltd is focused on advancing its RNA medicines platform, PRISM, which has shown potential through positive data in various programs targeting diseases like obesity and Duchenne muscular dystrophy. The anticipated initial data from the Phase 1 study of WVE-007 is expected to demonstrate significant efficacy in weight reduction and body composition improvement, coupled with a favorable safety profile, reinforcing the company’s capabilities in RNA editing. Collectively, these developments suggest a strong validation of WAVE’s innovative platform and its potential to deliver differentiated, best-in-class therapies in the RNA editing landscape.

Bears say

WAVE Life Sciences Ltd faces significant risks that could negatively impact its financial outlook, including the potential failure of key clinical studies such as WVE-004 and WVE-N531, which are crucial for the company's pipeline. Additionally, the inability to secure regulatory approval for these treatments poses a major hurdle that could thwart anticipated revenue generation from their product candidates. Lastly, the current data suggests challenges in achieving peak commercial revenue estimates for WVE-003 and WVE-N531, potentially due to limitations in market size, penetration, and pricing strategies.

WVE has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 12 analysts, WVE has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.